Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis

Summary

This is a Phase 2, multi center, randomized, placebo controlled parallel group study to evaluate the clinical efficacy and safety of LC51 0255 in subjects with moderately to severely active ulcerative colitis

Timeline

Start

2020-04

Primary completion

2021-11

Completion

2022-08

Outcome

Outcome not reported

Stopped: “company decision”

Drugs

Indications